Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,608JPY
2:00am EDT
Change (% chg)

¥18 (+1.13%)
Prev Close
¥1,590
Open
¥1,591
Day's High
¥1,609
Day's Low
¥1,570
Volume
5,446,400
Avg. Vol
7,985,282
52-wk High
¥1,804
52-wk Low
¥1,358

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥3,423,502.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 2.01

Financials

  4503.T Industry Sector
P/E (TTM): 15.81 36.61 36.60
EPS (TTM): 100.51 -- --
ROI: 16.06 14.46 13.91
ROE: 17.09 15.26 14.82

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

Sep 19 2016

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

Sep 19 2016

BRIEF-R&I affirms Astellas Pharma's rating at "AA" and says stable outlook - R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" - R&I

Sep 08 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

Aug 22 2016

UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal

Aug 22 Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

Aug 22 2016

BRIEF-Astellas Pharma submits new drug application for extended-release tablets of quetiapine fumarate in Japan

* Says it submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder

Aug 09 2016

BRIEF-Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

* Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration

Aug 08 2016

BRIEF-Astellas Pharma unit to sell Astellas Pharma Technologies to Avara

* Says its unit to sell Astellas Pharma Technologies, Inc. to Avara Norman Pharmaceutical Services, Inc (Avara) on Aug. 4 (U.S time)

Aug 04 2016

BRIEF-Astellas to transfer U.S. manufacturing unit to Avara

* Astellas announces transfer of U.S. manufacturing subsidiary to Avara

Aug 03 2016

BRIEF-Cytokinetics Inc reports q2 2016 financial results

* Will not update financial guidance until Q3 earnings due to recent expansion of collaboration with Astellas

Jul 28 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Pechala's Reports
$25.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.